What is Xeltis?
Headquartered with operations spanning the Netherlands and the United States, Xeltis operates at the intersection of advanced materials science and clinical medicine. The firm specializes in restorative devices, specifically heart valves and small-diameter blood vessels, which are engineered to integrate with the patient's own tissue. By moving beyond traditional prosthetic solutions, Xeltis aims to provide long-term, durable outcomes for patients requiring coronary artery bypass graft surgery or vascular access for hemodialysis. As a clinical-stage entity, the company remains focused on rigorous trial protocols to demonstrate the efficacy and safety of its restorative platform.
How much funding has Xeltis raised?
Xeltis has raised a total of $113.4M across 4 funding rounds:
Series B
$3.3M
Series C
$52.8M
Series D
$34M
Other Financing Round
$23.3M
Series B (2015): $3.3M with participation from VI Partners, Kurma Partners, and Life Sciences Partners
Series C (2017): $52.8M led by VI Partners, Kurma Partners, Life Sciences Partners, and Ysios Capital
Series D (2023): $34M supported by Invest-NL, Grand Pharmaceutical Group, and EQT Life Sciences
Other Financing Round (2026): $23.3M featuring VI Partners, DaVita, EQT, Invest-NL, and The European Innovation Council
Key Investors in Xeltis
VI Partners
VI Partners is the longest-established Swiss VC firm. For more than 20 years, VI Partners has been supporting innovative Healthcare and Technology companies, investing over CHF 250m in 55 ventures.
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in investing at various maturity stages from inception to capital expansion.
EQT
EQT Private Capital Europe & North America is the private-capital investment platform of EQT focused on partnering with companies across their development stages, with particular expertise in healthcare and technology.
What's next for Xeltis?
With the recent influx of capital, Xeltis is well-positioned to advance its clinical trial pipeline and scale its operational capabilities. The strategic focus will likely center on navigating the complex regulatory landscape required for the commercialization of its investigational devices. By leveraging the expertise of its diverse investor base, the company is poised to transition from a research-heavy development phase toward a more mature commercialization strategy, potentially setting a new standard in restorative cardiovascular care.
See full Xeltis company page
